Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans
- PMID: 3110215
- PMCID: PMC442200
- DOI: 10.1172/JCI113062
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans
Abstract
Lipid A-free polysaccharide (PS) isolated from Pseudomonas aeruginosa immunotype 5 lipopolysaccharide (LPS) was covalently coupled to toxin A via reductive amination. The PS-toxin A conjugate was comprised of 29.8% PS and 70.2% toxin A, possessed a molecular weight of greater than 1 X 10(6), was nontoxic for animals and was nonpyrogenic for rabbits at a dose of 50 micrograms/kg body wt when administered intravenously. The conjugate evoked only mild, transient reactions upon subcutaneous administration to human volunteers. Vaccination engendered immunoglobulin G (IgG) antibody, which neutralized the cytotoxic effect of toxin A and promoted the uptake and killing of P. aeruginosa in the presence of human polymorphonuclear leukocytes. Passively transferred IgG isolated from the serum of immunized donors was far more effective at preventing fatal P. aeruginosa burn wound sepsis than paired preimmunization serum. These studies establish the potential usefulness of such a PS-toxin A conjugate as a vaccine against P. aeruginosa.
Similar articles
-
Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.J Lab Clin Med. 1988 Jun;111(6):701-7. J Lab Clin Med. 1988. PMID: 3131471
-
Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.Infect Immun. 1986 Apr;52(1):161-5. doi: 10.1128/iai.52.1.161-165.1986. Infect Immun. 1986. PMID: 3082756 Free PMC article.
-
Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans.J Infect Dis. 1991 May;163(5):1040-5. doi: 10.1093/infdis/163.5.1040. J Infect Dis. 1991. PMID: 1708398
-
Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.Rev Infect Dis. 1987 Sep-Oct;9 Suppl 5:S644-9. doi: 10.1093/clinids/9.supplement_5.s644. Rev Infect Dis. 1987. PMID: 3120274 Review.
-
Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.Behring Inst Mitt. 1997 Feb;(98):269-73. Behring Inst Mitt. 1997. PMID: 9382750 Review.
Cited by
-
Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.Clin Exp Immunol. 2005 Nov;142(2):381-7. doi: 10.1111/j.1365-2249.2005.02925.x. Clin Exp Immunol. 2005. PMID: 16232228 Free PMC article. Clinical Trial.
-
The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria.Vaccines (Basel). 2023 Jul 20;11(7):1264. doi: 10.3390/vaccines11071264. Vaccines (Basel). 2023. PMID: 37515079 Free PMC article. Review.
-
Potential targets for next generation antimicrobial glycoconjugate vaccines.FEMS Microbiol Rev. 2018 May 1;42(3):388-423. doi: 10.1093/femsre/fuy011. FEMS Microbiol Rev. 2018. PMID: 29547971 Free PMC article. Review.
-
Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.Infect Immun. 1990 Feb;58(2):373-7. doi: 10.1128/iai.58.2.373-377.1990. Infect Immun. 1990. PMID: 2105272 Free PMC article.
-
Pseudomonas aeruginosa PAO-1 Lipopolysaccharide-Diphtheria Toxoid Conjugate Vaccine: Preparation, Characterization and Immunogenicity.Jundishapur J Microbiol. 2015 Jun 27;8(6):e17712. doi: 10.5812/jjm.8(5)2015.17712. eCollection 2015 Jun. Jundishapur J Microbiol. 2015. PMID: 26301059 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources